Cargando…

Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy

Detalles Bibliográficos
Autores principales:	Ganjalikhani-Hakemi, Mazdak, Xu, Ling, Zamyatnin, Andrey A., Bazhin, Alexandr V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936063/ https://www.ncbi.nlm.nih.gov/pubmed/35321430 http://dx.doi.org/10.3389/fonc.2022.872300

Ejemplares similares

The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies
por: Soltani, Mojdeh, et al.
Publicado: (2021)

TIM-3/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines
por: Rezaei, Mahnaz, et al.
Publicado: (2023)

TIM-3 in Leukemia; Immune Response and Beyond
por: Rezaei, Mahnaz, et al.
Publicado: (2021)

PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia
por: Soltani, Mojdeh, et al.
Publicado: (2023)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead
por: Aru, Basak, et al.
Publicado: (2022)

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
por: Bidram, Maryam, et al.
Publicado: (2021)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2023)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
por: Lapuente-Santana, Óscar, et al.
Publicado: (2020)

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
por: Shapoorian, Hooriyeh, et al.
Publicado: (2021)

Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality
por: Zalpoor, Hamidreza, et al.
Publicado: (2022)

siRNA Delivery Improvement by Co-formulation of Different Modified Polymers in Erythroleukemic Cell Line K562
por: Ganjalikhani hakemi, Mazdak, et al.
Publicado: (2013)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Semaphorin-3A as An Immune Modulator Is Suppressed by MicroRNA-145-5p
por: Rezaeepoor, Mahsa, et al.
Publicado: (2018)

Biomarkers for immune checkpoint blockers
por: Wienand, Kirsty, et al.
Publicado: (2018)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Editorial: Murine Models of Leukemia and Lymphoma
por: Cutucache, Christine E., et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis
por: Gómez-Llobell, Marina, et al.
Publicado: (2022)

Immune Checkpoint Blockers and Ovarian Cancer
por: Bose, Chinmoy K
Publicado: (2017)

Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine
por: Soltanpour Gharibdousti, Faezeh, et al.
Publicado: (2020)

Experimental postoperative ileus: is Th2 immune response involved?
por: Lin, Sisi, et al.
Publicado: (2021)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
por: Talaei, Zahra, et al.
Publicado: (2017)

Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)
por: Bakhtiari, Tahereh, et al.
Publicado: (2023)

Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia
por: Radpour, Ramin, et al.
Publicado: (2021)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma
por: Farahani, Rahim, et al.
Publicado: (2014)

Genetic defects and the role of helper T-cells in the pathogenesis of common variable immunodeficiency
por: Yazdani, Reza, et al.
Publicado: (2014)

Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma
por: Xu, Tianqi, et al.
Publicado: (2021)

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
por: Huang, Qian, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoints and Innovative Therapies in Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Outcome of Corneal Collagen Cross-Linking in Keratoconus: Introducing the Predictive Factors
por: Peyman, Alireza, et al.
Publicado: (2020)

Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma
por: Fathi, Farshid, et al.
Publicado: (2021)

Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study
por: Navabi, Parnian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i2brp3kom05ccvjreuq1ou52p6